Unveiling potential drug targets for lung squamous cell carcinoma through the integration of druggable genome and genome-wide association data

Lung squamous cell carcinoma (LSCC) is a major subtype of lung cancer with poor prognosis and low survival rate. Compared with lung adenocarcinoma, yet no FDA-approved targeted-therapy has been found for lung squamous cell carcinoma.